Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.19    0.00 (0.00%)
Bid:
0.18
Ask:
0.20
Spread: 0.02 (11.111%)
Market Cap: £1.41m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Interim Results

26 Sep 2006 16:46

Azure Holdings PLC26 September 2006 Azure Holdings Plc (" Company") Interim results for the six months ended 30 June 2006 Chairman's statement I am pleased to present the interim accounts for the six months ended 30 June2006. In the six months to 30 June 2006 the Company announced a loss after taxation of£138,000 (2005: £74,000). The figures should not reflect the future of the Company, which hopefully willmove forward successfully as ValiRx plc from early next month, because, asannounced on 11 September 2006, the reverse acquisition of ValiRx Limited hasbeen agreed and is subject to shareholders approval at the EGM scheduled for 2October 2006. If all the resolutions at that meeting are approved, the Company will retain itsAIM quotation and I will resign as Chairman leaving the new board and GerryDesler, Finance Director from the old board, to run the Company. Barry GoldChairman 26 September 2006 Azure Holdings plc Profit and Loss Account for the six months ended 30 June 2006 6 months ended 6 months ended Year ended 31 30 June 2006 30 June 2005 December 2005 (unaudited) (unaudited) (audited) £'000 £'000 £'000 Turnover - - - Administrative expenses (138) (74) (134) Operating loss (138) (74) (134) Loss on ordinary activities before taxation (138) (74) (134) Tax on loss on ordinary activities - - - Loss on ordinary activities after taxation (138) (74) (134) Retained loss for the period (138) (74) (134) Loss per ordinary share (0.12p) (0.15p) (0.28p) The profit and loss account has been prepared on the basis that all operationsare continuing operations. All recognised gains or losses are dealt withthrough the profit and loss account or statement of recognised gains and losses. Azure Holdings plc Balance Sheet as at 30 June 2006 30 June 2006 30 June 2005 31 December 2005 (unaudited) (unaudited) (audited) £'000 £'000 £'000Current assetsDebtors 9 3 1Cash at bank and in hand 127 1 1 136 4 2 Creditors: amounts falling due within one year (103) (147) (205) Net current assets/(liabilities) 33 (143) (203) Total assets less current liabilities 33 (143) (203) Net (liabilities)/assets 33 (143) (203) Capital and reservesCalled up Share Capital 6,271 5,475 5,475Share Premium 9,858 10,279 10,279Profit and loss account (16,096) (15,897) (15,957) Equity shareholders funds 33 (143) (203) Azure Holdings plc Cash Flow Statement for the six months ended 30 June 2006 6 months ended 6 months ended 30 June 2006 30 June 2005 (unaudited) (unaudited) £'000 £'000Net cash inflow (outflow) from operating activities (249) (13) FinancingIssue of ordinary shares 796 - Share premium reduction arising onconversion of loan stock (421) - Increase/(Decrease) in cash 126 (13) Azure Holdings plc Notes to the Interim Results 1. The interim results are unaudited and do not constitute statutoryaccounts within the meaning of section 240 of the Companies Act 1985. Thefigures for the year ended 31 December 2005 have been extracted from thestatutory accounts filed with the registrar of companies on which the auditorsgave an unqualified report. 2. The interim results have been prepared using the accountingpolicies set out in the statutory accounts for the year ended 31 December 2005. 3. The comparative figures for the unaudited interim results for theperiod ended 30 June 2005 are stated as announced on 27 September 2005. 4. Loss per share The loss per share for the six months ended 30 June 2006 has been calculated onthe basis of the loss after taxation for the period of £138,000 (2005: £74,000) and the weighted average number of shares in issue during the period of118,717,810 (2005: 48,317,569). . 5. The directors do not propose to pay a dividend for the period. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Jun 20267:00 amRNSConclusion of Evaluation with Stingray
1st Jun 20267:00 amRNSValiRx Exercises Option on Evaluation Asset
27th May 20267:00 amRNSCytolytix Patent Granted
21st May 20267:00 amRNSResult of Oversubscribed WRAP Retail Offer
18th May 20267:00 amRNSWRAP Retail Offer for up to £150,000
15th May 20267:00 amRNSFundraising of up to £1,155,000
31st Mar 202610:15 amRNSChange of Registered Office
26th Mar 20267:00 amRNSValiRx Commercial Update Q1 2026
24th Mar 20267:00 amRNSValiRx and TwinEdge to present Digital Twin data
4th Mar 20267:00 amRNSDirector/PDMR Shareholding
2nd Mar 20267:00 amRNSValiRx forms ValiRx Animal Health Ltd subsidiary
19th Jan 20267:00 amRNSExercise of Warrants
9th Jan 20263:45 pmRNSReplacement: Evaluation and Transfer Agreement
9th Jan 20267:00 amRNSNew Evaluation and Material Transfer Agreement
8th Jan 20261:00 pmRNSHolding(s) in Company
5th Dec 202510:56 amRNSHolding(s) in Company
24th Nov 20253:54 pmRNSHolding(s) in Company
24th Nov 20259:30 amRNSHolding(s) in Company
20th Nov 202512:11 pmRNSResult of GM & Issue of Equity
13th Nov 20252:16 pmRNSHolding(s) in Company
10th Nov 20257:00 amRNSHolding(s) in Company
4th Nov 20255:15 pmRNSPosting of Circular and Notice of General Meeting
4th Nov 20257:00 amRNSResult of WRAP Retail Offer
30th Oct 20257:21 amRNSWRAP Retail Offer for up to £300,000
30th Oct 20257:17 amRNSFundraising of up to £1,050,000
14th Oct 20257:00 amRNSInaphaea Commercial update
29th Sep 20257:00 amRNSHalf-year Report
18th Sep 20257:00 amRNSInaphaea Commercial Update
1st Sep 20257:00 amRNSCytolytix Commercial update
26th Aug 20257:00 amRNSCommercial update
7th Aug 202510:51 amRNSValiRx Awarded Grant from Open University
5th Aug 20259:53 amRNSUpdate on Evaluation Agreement with Stingray Bio
4th Aug 20257:00 amRNSLicensing Agreement with Dominion Biotech Ltd
29th Jul 20257:00 amRNSCollaboration Agreement with Voxcell BioInnovation
30th Jun 20253:48 pmRNSResult of AGM
20th Jun 20257:00 amRNSAmbrose Exercise Option on VAL401
9th Jun 202510:57 amRNSValiRx Investor Webinar
6th Jun 202510:54 amRNSHolding(s) in Company
6th Jun 20257:00 amRNSFinal Results & Notice of AGM
3rd Jun 20257:00 amRNSNew Evaluation and Material Transfer Agreement
20th May 20251:25 pmRNSHolding(s) in Company
12th May 20257:00 amRNSInaphaea Deal Extension With Dominion
30th Apr 20257:00 amRNSCommercial Update
3rd Apr 20257:00 amRNSTermination of Letter of Intent with TheoremRx
27th Mar 20257:00 amRNSDirectorate Changes and new Advisory Board
21st Mar 202511:07 amRNSDirector Disclosure Update
24th Feb 20257:00 amRNSConclusion of Evaluation Project
3rd Feb 20257:00 amRNSInaphaea Evaluation and Commercial Use Agreement
30th Jan 20257:00 amRNSExtension of Evaluation Agreement
29th Jan 20257:00 amRNSNew Evaluation and Option Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.